Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting

Highlights

• The incidence of tuberculosis (TB) in Allo-HSCT recipients in France is approximately 60 per 100,000 patient-years, significantly higher than the general population.
• Birth in a high-incidence country for TB remains the most significant independent risk factor (OR = 19.4).
• Clinical presentation is predominantly extrapulmonary (82%), with a median onset of 147 days post-transplantation.
• Severe adverse reactions to anti-tuberculous therapy occur in 25% of cases, complicating post-transplant recovery.

Background

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative modality for various hematologic malignancies and nonmalignant disorders, such as thalassemia and sickle cell disease. However, the requisite conditioning regimens and subsequent immunosuppression—particularly T-cell depletion—render recipients highly susceptible to opportunistic infections. While viral and fungal pathogens are frequently prioritized in clinical protocols, Mycobacterium tuberculosis (TB) remains a formidable challenge, especially when cases occur in countries with low background incidence.

In nations like France, the rarity of TB can lead to diagnostic delays. Furthermore, as global migration patterns evolve, transplant centers in low-incidence regions increasingly treat patients born in endemic areas. The clinical burden of managing such complications is substantial; as seen in broader hematologic studies (e.g., healthcare resource utilization in thalassemia), the economic and clinical weight of managing secondary complications often exceeds the initial treatment costs. This article synthesizes findings from a decade-long nationwide study to refine risk stratification and management strategies for TB in the Allo-HSCT population.

Key Content

Epidemiology and Incidence Rates

Analysis of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) database between 2012 and 2023 identified 35 cases of TB among adult Allo-HSCT recipients. The calculated incidence rate of 60 per 100,000 patient-years underscores that while TB is rare in absolute terms within low-incidence countries, the relative risk for the Allo-HSCT population is markedly elevated compared to the general public. This mirrors trends in other chronic hematologic conditions where systemic vulnerability increases the risk of high-burden pathologies.

Risk Factor Analysis

The study’s multivariate analysis revealed that the single most potent predictor of post-transplant TB was being born in a high-incidence country (OR = 19.4; 95% CI: 4.49–135.79; p < 0.001). This suggests that post-transplant TB is predominantly a result of the reactivation of Latent Tuberculosis Infection (LTBI) under the pressure of pharmacological immunosuppression rather than de novo infection. This finding aligns with global health initiatives (as discussed in literature regarding sub-Saharan African disease burden) that emphasize the necessity of robust screening programs in high-risk demographics.

Clinical Manifestations and Diagnostic Timing

The median interval between transplantation and TB diagnosis was 147 days (range: 30–7244 days), placing the majority of cases within the first six months post-engraftment—a period characterized by profound T-cell deficiency.

Notably, the study found that 82% of patients presented with extrapulmonary involvement. This high rate of disseminated or localized non-pulmonary disease (e.g., osteoarticular, lymph node, or central nervous system TB) complicates the diagnostic pathway. Unlike typical pulmonary TB, which might be flagged by routine imaging or cough, extrapulmonary TB requires a high index of clinical suspicion and often invasive biopsy for microbiological confirmation.

Therapeutic Outcomes and Safety Profiles

The median duration of anti-tuberculous therapy was 273 days. The management of TB in this cohort is fraught with pharmacological challenges:

• Drug-Drug Interactions: Rifamycins, a cornerstone of TB treatment, are potent inducers of cytochrome P450 enzymes, which can critically lower the serum levels of calcineurin inhibitors and other immunosuppressants, risking Graft-versus-Host Disease (GvHD).
• Toxicity: 25% of the study cohort experienced severe adverse reactions to anti-TB medications, requiring treatment modification. This is a significantly higher rate than observed in the immunocompetent population.
• Mortality: TB-attributable mortality was 9%, highlighting the severity of the infection when it strikes the post-transplant patient.

Expert Commentary

The findings by Imbert de Trémiolles et al. provide a critical roadmap for transplant physicians. The overwhelming correlation between birth origin and TB reactivation suggests that current LTBI screening protocols in low-incidence countries may be insufficient or inconsistently applied to transplant candidates.

There is a clear clinical mandate for the implementation of Interferon-Gamma Release Assays (IGRAs) or Tuberculin Skin Tests (TST) for all candidates born in endemic regions. If LTBI is detected, prophylactic treatment prior to or immediately following transplant should be considered, weighing the risk of hepatotoxicity against the high morbidity of active TB. Furthermore, the prevalence of extrapulmonary symptoms means that clinicians should not rule out TB based solely on a clear chest X-ray in a symptomatic patient with a high-risk background.

From a translational perspective, the use of point-of-care diagnostics (similar to the HemoScreen technologies discussed in recent laboratory evaluations) for rapid screening or the development of more sensitive biomarkers for early reactivation could drastically improve outcomes. The high rate of drug toxicity also suggests a need for newer, less toxic anti-mycobacterial regimens tailored for the transplant setting.

Conclusion

Tuberculosis post-Allo-HSCT in low-incidence countries is a rare but life-threatening complication characterized by early reactivation and frequent extrapulmonary involvement. Risk is disproportionately concentrated in patients from endemic regions, making targeted LTBI screening an essential component of pre-transplant workup. While the overall mortality is manageable, the high rate of drug-related toxicity and the complexity of managing extrapulmonary disease necessitate a multidisciplinary approach involving transplant specialists and infectious disease experts. Future research should focus on the safety of shorter, rifamycin-free regimens to minimize hazardous drug-drug interactions in this vulnerable population.

References

• Imbert de Trémiolles G, et al. Tuberculosis after allogeneic hematopoietic stem cell transplantation: a decade nationwide case-control retrospective study in low-incidence country. Bone marrow transplantation. 2026-03-10. PMID: 41807605.
• Global Burden of Disease Study 2021. High body-mass index and multiple myeloma risk. Hematology. 2026. PMID: 41808030.
• Lafont E, et al. Management of infectious complications in Allo-HSCT recipients. SFGM-TC Guidelines. 2024.